Biodesix to Present New Data on Nodify Lung Testing at CHEST 2023 Annual Meeting

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be presented at the CHEST Annual Meeting 2023 in Honolulu, Hawaiʻi. These presentations will provide new insight on the clinical utility and real-world impact of the Nodify CDT and Nodify XL2 tests in the comprehensive management of lung nodules.

The first abstract, titled "Real-World Impact of a Blood-Based Integrated Classifier on the Management of Benign Solid, Part-Solid, and Ground Glass Pulmonary Nodules," will be presented by Jonathan Kurman, MD, Director of Interventional Pulmonology at the Medical College of Wisconsin, on Tuesday, October 10 at 12:00 pm HT (6:00 pm ET). The presentation will delve into subgroup analyses from the prospective, real-world ORACLE study (NCT03766958), evaluating the clinical utility of the Nodify XL2 test across the spectrum of nodule types. The recently published primary endpoint of the study highlighted a 74% reduction in invasive procedures on benign nodules with use of the test. The analysis will demonstrate that this reduction is consistent across solid, part-solid, and ground glass lung nodules.

Dr. Kurman, remarked, "The data we're presenting at CHEST 2023 underscores the transformative potential of the Nodify XL2 test in managing all types of lung nodules. Clinical guidelines recommend different management strategies for solid versus non-solid nodules and this data indicates the test can be used broadly to avoid unnecessary invasive procedures."

The second abstract, titled "Comparison of a High Specificity Blood-Based Biomarker with PET/CT for Identifying Malignant Pulmonary Nodules," will be presented by Kathryn Long, MD, Pulmonary and Critical Care Fellow at the Medical University of South Carolina, on Wednesday, October 11 at 12:00 pm HT (6:00 pm ET). The presentation will demonstrate the complementary nature of the Nodify CDT test and PET/CT imaging results. PET/CT is a common imaging technique that detects abnormal levels of cellular metabolism and is clinically valuable in detecting cancer that has spread throughout the body. However, published data shows that the performance of PET/CT imaging alone is compromised in assessing small lung nodules for cancer. The analysis will demonstrate that the Nodify CDT test alongside PET/CT improves the performance, identifying malignant nodules with a high level of accuracy.